1. Home
  2. TVRD vs BYND Comparison

TVRD vs BYND Comparison

Compare TVRD & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • BYND
  • Stock Information
  • Founded
  • TVRD 2017
  • BYND 2009
  • Country
  • TVRD United States
  • BYND United States
  • Employees
  • TVRD N/A
  • BYND N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • BYND Packaged Foods
  • Sector
  • TVRD Health Care
  • BYND Consumer Staples
  • Exchange
  • TVRD Nasdaq
  • BYND Nasdaq
  • Market Cap
  • TVRD 246.5M
  • BYND 258.5M
  • IPO Year
  • TVRD N/A
  • BYND 2019
  • Fundamental
  • Price
  • TVRD $29.44
  • BYND $3.46
  • Analyst Decision
  • TVRD Strong Buy
  • BYND Sell
  • Analyst Count
  • TVRD 5
  • BYND 3
  • Target Price
  • TVRD $59.20
  • BYND $4.00
  • AVG Volume (30 Days)
  • TVRD 93.5K
  • BYND 1.6M
  • Earning Date
  • TVRD 08-21-2025
  • BYND 08-06-2025
  • Dividend Yield
  • TVRD N/A
  • BYND N/A
  • EPS Growth
  • TVRD N/A
  • BYND N/A
  • EPS
  • TVRD N/A
  • BYND N/A
  • Revenue
  • TVRD N/A
  • BYND $319,580,000.00
  • Revenue This Year
  • TVRD N/A
  • BYND N/A
  • Revenue Next Year
  • TVRD N/A
  • BYND $3.36
  • P/E Ratio
  • TVRD N/A
  • BYND N/A
  • Revenue Growth
  • TVRD N/A
  • BYND N/A
  • 52 Week Low
  • TVRD $8.13
  • BYND $2.23
  • 52 Week High
  • TVRD $34.31
  • BYND $9.24
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • BYND 54.68
  • Support Level
  • TVRD N/A
  • BYND $3.45
  • Resistance Level
  • TVRD N/A
  • BYND $3.62
  • Average True Range (ATR)
  • TVRD 0.00
  • BYND 0.14
  • MACD
  • TVRD 0.00
  • BYND -0.02
  • Stochastic Oscillator
  • TVRD 0.00
  • BYND 46.15

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: